KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2016 - 2025)

Teva Pharmaceutical Industries' Other Accumulated Expenses history spans 17 years, with the latest figure at $1.2 billion for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 15.88% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, up 15.88%, and an annual FY2025 reading of $1.2 billion, up 15.88% over the prior year.
  • Other Accumulated Expenses for Q4 2025 was $1.2 billion at Teva Pharmaceutical Industries, up from $1.1 billion in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.2 billion in Q3 2024, with the low at $739.0 million in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $992.3 million, with a median of $986.5 million recorded in 2023.
  • Year-over-year, Other Accumulated Expenses crashed 30.35% in 2021 and then increased 22.75% in 2024.
  • Tracing TEVA's Other Accumulated Expenses over 5 years: stood at $903.0 million in 2021, then grew by 11.3% to $1.0 billion in 2022, then grew by 3.88% to $1.0 billion in 2023, then dropped by 2.3% to $1.0 billion in 2024, then grew by 15.88% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Other Accumulated Expenses are $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $940.0 million (Q2 2025).